BDSX News and Press, Biodesix Inc. From 12/19/22

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced positive coverage decisions from four private payers including Blue Cross Blue Shield of North Carolina, Blue Cross Blue Shield of South Carolina, Blue Cross Blue Shie...

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the appointment of Lawrence (Lair) T. Kennedy, Jr. to the Company’s Board of Directors (Board) and Audit Committee of the Board effective January 3, 2023. Mr. K...

Biodesix, Inc . (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that the Company was named the leading Proteomics Solutions Company in the U.S. by Life Sciences Review Magazine , featured in the December 2022 issue, &#...

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the closing of its underwritten public offering of 35,075,000 shares of its common stock at a price to the public of $1.15 per share, including the exercis...

Biodesix ( NASDAQ: BDSX ) has priced an underwritten public offering of 30.5M shares of its common stock at a price to the public of $1.15/share. The gross proceeds to Biodesix from the offering are expected to be $35.1M. Offering is expected to close on November 21, 2...

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the pricing of an underwritten public offering of 30,500,000 shares of its common stock at a price to the public of $1.15 per share, before underwriting di...

Diagnostic solutions company Biodesix ( NASDAQ: BDSX ) has obtained a term loan facility for up to $50M from the healthcare investment firm Perceptive Advisors. Biodesix will receive an initial $30M funding, and an additional $20M will be available in two separat...

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it has commenced an underwritten public offering of $30 million of shares of its common stock, before deducting underwriting discounts and commissions...

$30 million initial funding $20 million in future revenue milestone-based funding Strengthens balance sheet and extends runway with five-year interest only period Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions compan...

Data confirms the ability of the VeriStrat ® test to predict outcomes in patients with Non-small Cell Lung Cancer treated with immunotherapy regimens Biodesix, Inc . (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease,...